NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

GR Defect in Sputum Cells in COPD

WithdrawnN/A

Sponsor: Imperial College London

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Induced Sputum

Countries: United Kingdom

To investigate a possible mechanism of the GR defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR-GRE binding, expression of inflammatory and anti-inflammatory factors such as IL-6, IL-8, MKP-1, GILZ, SLPI production in sputum cells

Eligibility overview

Sex: ALL

Age: 35 Years to 85 Years

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with moderate (stage II, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers.
* Written informed consent

Exclusion Criteria:

* Current upper respiratory tract infections
* Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
* Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason

Locations (1)

London, United Kingdom